The BA.3.2 variant, commonly referred to as the Cicada variant, was first identified in South Africa in November 2024. This variant is a descendent of BA.3, an omicron subvariant that emerged in 2022. With approximately 70 to 75 mutations in its spike protein, the Cicada variant has raised concerns among health experts regarding its transmissibility and potential impact on public health.

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. Most cases of the Cicada variant appear mild to moderate, resembling flu-like illness, especially among vaccinated individuals. Health experts have noted that symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains.

Current evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier variants. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This reassurance is echoed by health authorities who emphasize that most cases can be managed at home with rest and hydration.

Despite the presence of multiple mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. However, some experts warn that the current COVID-19 vaccines may not be as effective against the Cicada variant due to its numerous mutations. Observers are closely monitoring the situation as the variant has been detected in over 20 countries and is currently on the rise in the United States, with reports of cases in at least 25 states.

Health authorities recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the Cicada variant. The variant primarily spreads through respiratory droplets and close contact in crowded or poorly ventilated spaces, which underscores the importance of public health measures.

As the situation evolves, health experts continue to analyze the implications of the Cicada variant. They emphasize that symptoms of the BA.3.2 Cicada variant are largely similar to earlier Omicron strains, with no new or unusual signs reported so far. However, details remain unconfirmed regarding the long-term effects of this variant and its potential to evade immune responses.

In summary, while the emergence of the Cicada variant has prompted increased vigilance among health authorities, the current understanding suggests that it does not significantly alter the landscape of COVID-19 severity. Continued monitoring and adherence to health guidelines remain crucial as the situation develops.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on newsrush.

The cicada COVID variant, officially designated as BA.3.2, is causing significant concern among health officials due to its potential to evade immunity from vaccines and previous infections. As of February 2026, this heavily mutated variant has been detected in at least 25 states across the United States, raising alarms about its spread and impact on public health.

First identified in South Africa in November 2024, BA.3.2 has since been classified as a ‘variant under monitoring’ by the World Health Organization (WHO) since December 2025. The variant is characterized by an alarming 70 to 75 mutations in its spike protein, which may significantly reduce the effectiveness of existing vaccines against infection, though they are still expected to provide protection against severe disease.

Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues. Despite its rapid spread, experts have noted that BA.3.2 is not currently causing more severe disease or hospitalizations compared to previous strains. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.”

The variant’s unusual emergence pattern has led to its nickname, ‘cicada’, drawing a parallel to the lifecycle of the insect. This nomenclature reflects the variant’s sudden appearance and potential for resurgence, similar to the periodic emergence of cicadas in nature.

As of February 11, 2026, BA.3.2 has been detected in at least 23 countries, with a notable presence in Denmark, Germany, and the Netherlands, where it accounts for approximately 30% of cases. In the U.S., about 3.7% of sewage samples nationwide have shown the presence of BA.3.2, indicating its growing prevalence.

Experts like Andrew Pekosz, Ph.D., have expressed concerns about the variant’s mutations, stating, “It has a lot of mutations that may cause it to look different to your immune system.” This raises questions about the long-term efficacy of current vaccines. However, vaccination remains a crucial tool in limiting cases and preventing severe outcomes.

Despite the challenges posed by BA.3.2, the exact reasons for its resurgence remain unclear, and the long-term impact on public health is uncertain. As health authorities continue to monitor the situation, further developments are expected in the ongoing battle against COVID-19.

The post Cicada COVID Variant: The Emergence of BA.3.2 appeared first on newsrush.